List of Nuedexta drug patents
Nuedexta is owned by Avanir Pharms.
Nuedexta contains Dextromethorphan Hydrobromide; Quinidine Sulfate.
Nuedexta has a total of 2 drug patents out of which 0 drug patents have expired.
Nuedexta was authorised for market use on 29 October, 2010.
Nuedexta is available in capsule;oral dosage forms.
Nuedexta can be used as treatment of pseudobulbar affect.
The generics of Nuedexta are possible to be released after 13 August, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227484 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Jul, 2023
(5 months from now) | |
| US7659282 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Aug, 2026
(3 years from now) | |
Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Treatment of pseudobulbar affect
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic